Catch up on the top radiology content of the past week.
|Articles|September 1, 1999
ADAC struggles continue in Q3
An 8% increase in quarterly revenues wasn’t enough to restore ADAC Laboratories to profitability. The nuclear medicine and healthcare information systems vendor reported revenues of $75.6 million for the quarter (end-July 4), compared with revenues
Advertisement
An 8% increase in quarterly revenues wasnt enough to restore ADAC Laboratories to profitability. The nuclear medicine and healthcare information systems vendor reported revenues of $75.6 million for the quarter (end-July 4), compared with revenues of $69.8 million for the third quarter of 1998. Net loss for the quarter, however, was $5.4 million, compared with net income of $3.4 million in the same period a year ago. The unsatisfactory earnings report was the latest in a series of disappointments for the Milpitas, CA-based firm, which has been beset by a decline in nuclear medicine market share and an earnings restatement that took place in late 1998 (SCAN 8/4/99).
These financial results put ADAC out of compliance with its $75 million revolving credit facility, and the company is negotiating an amendment to the facility that will include a waiver of its third-quarter default as well as modified financial covenants that better reflect the companys current financial performance. As of Aug. 24, ADAC stock was trading at $6.31; slightly above its 52-week low of $5.75 but well below its high of $22.75. Revenues are expected to rise again in the fourth quarter, according to Andrew Eckert, ADAC chairman and CEO.
Advertisement
Related to this article
While a new article raises provocative questions about the capability of photon-counting CT (PCCT) to perhaps replace diagnostic ICA, the real revolution with this modality is going beyond stenosis measurement to a renewed focus on the disease of atherosclerosis.
The use of adjunctive CT bone reading software in women with breast cancer detected between 8 to 22 percent more metastatic lesions for reviewing radiologists and reduced CT interpretation time by 50 percent or more, according to a new study.
Catch up on the top radiology content of the past week.
Catch up on the top radiology content of the past week.
Catch up on key neuroradiology news and research from the past month, including recently published studies involving white matter hyperintensity findings on brain MRI, MRI-enhanced amyloid PET and the newly FDA-approved PET agent floretyrosine F18 for glioma imaging.
Magnetic resonance imaging offered a 29 percent higher sensitivity than CT for differentiating liver metastases, but CT provided 12 percent higher sensitivity than MRI for assessing vascular invasion, according to a new 40-study meta-analysis.
Does fractional flow reserve (FFR) or quantitative plaque burden from CCTA provide greater prognostic insight into coronary disease?
Advertisement
Advertisement
Trending on Diagnostic Imaging
1
FDA Clears MRI-Based AI Software for Prognostic Evaluation of Patients with Mild Cognitive Impairment
2
Can MRI-Based AI Have an Impact in Reducing Unnecessary Prostate Biopsies?
3
The Reading Room Podcast: A Closer Look at New Research on 177Lu-Edotreotide for Treating GEP-NETs
4
How AI, Theranostics and More Empowered Patients Have Led to Significant Changes in Radiology
5